We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
BIO-RAD LABORATORIES

Download Mobile App




Structure of Enzyme for Trehalose Synthesis May Promote Drug Development

By LabMedica International staff writers
Posted on 29 Jun 2016
Print article
Image: This ribbon diagram shows two views of the structure of the enzyme Tps2 as it removes a phosphate from a sugar molecule (yellow, orange, and red). The result of this process is trehalose, which forms a tough coating on pathogenic fungi, enabling them to make the transition from the ambient temperature of the environment to the much hotter temperature inside a human host (Photo courtesy of Yi Miao, Duke University).
Image: This ribbon diagram shows two views of the structure of the enzyme Tps2 as it removes a phosphate from a sugar molecule (yellow, orange, and red). The result of this process is trehalose, which forms a tough coating on pathogenic fungi, enabling them to make the transition from the ambient temperature of the environment to the much hotter temperature inside a human host (Photo courtesy of Yi Miao, Duke University).
A team of molecular microbiologists has established the molecular structure of an enzyme required for synthesis of trehalose, a sugar required by several different pathogenic fungi.

To survive in the human host, pathogenic fungi require the disaccharide trehalose, which is formed by a 1,1-glucoside bond between two alpha-glucose units. Trehalose acts to protect the fungi from the high temperatures they experience while trying to colonize the human organism. The enzymes that synthesize trehalose are not found in humans, and thus serve as potential targets for novel antifungal drugs.

Investigators at Duke University (Durham, NC, USA) used x-ray crystallography to establish multiple structures for one of the trehalose biosynthetic enzymes, trehalose-6-phosphate phosphatase (Tps2), from Candida albicans.

In a paper published in the June 15, 2016, online edition of the journal Proceedings of the [U.S.] National Academy of Sciences the investigators said that these structures and germane in vivo and biochemical studies revealed the significance of the Tps2 N-terminal domain in fungal cellular stress responses and the conformational flexibility of the Tps2 C-terminal domain that imposed exquisite substrate specificity and permitted efficient catalysis.

"We found that the active site of this enzyme is identical in each of these pathogenic fungi, so they all use the same mechanism and have the same residues that are necessary for the production of trehalose," said senior author Dr. Richard G. Brennan, professor of biochemistry at Duke University. "By targeting those active sites, we hope to create a drug with broad-spectrum effect. If you could kill one fungus, you are going to kill them all; at least if you can get the drug inside."

Related Links:
Duke University

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: A blood test could predict lung cancer risk more accurately and reduce the number of required scans (Photo courtesy of 123RF)

Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans

Lung cancer is extremely hard to detect early due to the limitations of current screening technologies, which are costly, sometimes inaccurate, and less commonly endorsed by healthcare professionals compared... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The real-time multiplex PCR test is set to revolutionize early sepsis detection (Photo courtesy of Shutterstock)

1 Hour, Direct-From-Blood Multiplex PCR Test Identifies 95% of Sepsis-Causing Pathogens

Sepsis contributes to one in every three hospital deaths in the US, and globally, septic shock carries a mortality rate of 30-40%. Diagnosing sepsis early is challenging due to its non-specific symptoms... Read more

Pathology

view channel
Image: The QIAseq xHYB Mycobacterium tuberculosis Panel uses next-generation sequencing (Photo courtesy of 123RF)

New Mycobacterium Tuberculosis Panel to Support Real-Time Surveillance and Combat Antimicrobial Resistance

Tuberculosis (TB), the leading cause of death from an infectious disease globally, is a contagious bacterial infection that primarily spreads through the coughing of patients with active pulmonary TB.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.